Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

por Isaac, Krista, Mato, Anthony R
Publicado 2020

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

por Rhodes, Joanna M, Mato, Anthony R
Publicado 2021

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions

por Mato, Anthony R., Roeker, Lindsey E.
Publicado 2022

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia

por Thompson, Meghan C., Roeker, Lindsey E., Mato, Anthony R.
Publicado 2021

The potential of pirtobrutinib in multiple B-cell malignancies

por Jensen, Jeffrey L., Mato, Anthony R., Pena, Camila, Roeker, Lindsey E., Coombs, Catherine C.
Publicado 2022

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia

por Shadman, Mazyar, Liu, Catherine, Eakle, Katherine, Hiew, Hwai J., Biondo, Juliana M.L., Ghia, Paolo, Mato, Anthony R.
Publicado 2022

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

por Mato, Anthony R., Tang, Boxiong, Azmi, Soraya, Yang, Keri, Zhang, Xiaojuan, Stern, Jennifer C., Hedrick, Eric, Huang, Jane, Sharman, Jeff P.
Publicado 2022

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

por Roeker, Lindsey E., Knorr, David A., Pessin, Melissa S., Ramanathan, Lakshmi V., Thompson, Meghan C., Leslie, Lori A., Zelenetz, Andrew D., Mato, Anthony R.
Publicado 2020

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

por Roeker, Lindsey E., DerSarkissian, Maral, Ryan, Kellie, Chen, Yan, Duh, Mei Sheng, Wahlstrom, Svea K., Hakre, Shweta, Yu, Louise, Guo, Helen, Mato, Anthony R.
Publicado 2023

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry

por Mato, Anthony R., Ghosh, Nilanjan, Sharman, Jeff P., Brander, Danielle, Gutierrez, Meghan, Huang, Qing, Wu, Linda H., Young, Alex, Upasani, Sandhya, Naganuma, Maoko, Barrientos, Jacqueline C.
Publicado 2022

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase...

por Mato, Anthony R., Sharman, Jeff P., Biondo, Juliana M.L., Wu, Mei, Mun, Yong, Kim, Su Y., Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F.
Publicado 2020

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STU...

por Cohen, Jonathon, Roeker, Lindsey, Cheah, Chan, Eyre, Toby, Patel, Krish, Woyach, Jennifer, Seymour, John, Wang, Michael, Wang, Yucai, Loubert, Angely, Payakachat, Nalin, Hess, Lisa, Abada, Paolo, Mato, Anthony R., Ghia, Paolo
Publicado 2023

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry

por Mato, Anthony R., Barrientos, Jacqueline C., Ghosh, Nilanjan, Pagel, John M., Brander, Danielle M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Iyengar, Reethi, Ipe, David, Upasani, Sandhya, Amaya-Chanaga, Carlos I., Sundaram, Murali, Han, Jennifer, Giafis, Nick, Sharman, Jeff P.
Publicado 2019

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

por Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Publicado 2019

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

por Roeker, Lindsey E., Knorr, David A., Thompson, Meghan C., Nivar, Mariely, Lebowitz, Sonia, Peters, Nicole, Deonarine, Isaac, Momotaj, Saddia, Sharan, Saumya, Chanlatte, Vanessa, Hampton, Bianca, Butala, Liana, Amato, Lindsay, Richford, Angela, Lunkenheimer, Jessica, Battiato, Kristen, Laudati, Carissa, Mato, Anthony R.
Publicado 2021

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

por Feldman, Tatyana, Mato, Anthony R, Chow, Kar F, Protomastro, Ewelina A, Yannotti, Kara M L, Bhattacharyya, Pritish, Yang, Xiao, Donato, Michele L, Rowley, Scott D, Carini, Carolanne, Valentinetti, Marisa, Smith, Judith, Gadaleta, Gabriella, Bejot, Coleen, Stives, Susan, Timberg, Mary, Kdiry, Sabrina, Pecora, Andrew L, Beaven, Anne W, Goy, Andre
Publicado 2014

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN...

por Brown, Jennifer R., Desikan, Sai Prasad, Nguyen, Bastien, Won, Helen, Tantawy, Shady, Mcneely, Samuel Clark, Marella, Narasimha, Ebata, Kevin, Woyach, Jennifer, Patel, Krish, Tam, Constantine, Eyre, Toby, Cheah, Chan, Shah, Nirav N, Ghia, Paolo, Jurczak, Wojciech, Balbas, Minna, Nair, Binoj, Abada, Paolo, Wang, Chunxiao, Wang, Denise, Mato, Anthony R., Gandhi, Varsha, Wierda, William G.
Publicado 2023

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

por Mato, Anthony R., Nabhan, Chadhi, Thompson, Meghan C., Lamanna, Nicole, Brander, Danielle M., Hill, Brian, Howlett, Christina, Skarbnik, Alan, Cheson, Bruce D., Zent, Clive, Pu, Jeffrey, Kiselev, Pavel, Goy, Andre, Claxton, David, Isaac, Krista, Kennard, Kaitlin H., Timlin, Colleen, Landsburg, Daniel, Winter, Allison, Nasta, Sunita D., Bachow, Spencer H., Schuster, Stephen J., Dorsey, Colleen, Svoboda, Jakub, Barr, Paul, Ujjani, Chaitra S.
Publicado 2018

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

por Shanafelt, Tait D., Wang, Xin Victoria, Hanson, Curtis A., Paietta, Elisabeth M., O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong Christine, Coutre, Steven E., Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin, Kay, Neil E.
Publicado 2022

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

por Gill, Saar, Vides, Vanessa, Frey, Noelle V., Hexner, Elizabeth O., Metzger, Susan, O'Brien, Megan, Hwang, Wei-Ting, Brogdon, Jennifer L., Davis, Megan M., Fraietta, Joseph A., Gaymon, Avery L., Gladney, Whitney L., Lacey, Simon F., Lamontagne, Anne, Mato, Anthony R., Maus, Marcela V., Melenhorst, J. Joseph, Pequignot, Edward, Ruella, Marco, Shestov, Maksim, Byrd, John C., Schuster, Stephen J., Siegel, Donald L., Levine, Bruce L., June, Carl H., Porter, David L.
Publicado 2022